- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01760889
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
May 29, 2021 updated by: Shire
A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 26-week, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 Low Dose Range (40mg, 80mg, 100mg) and High Dose Range (120mg, 140mg, 160mg) as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
Study Overview
Status
Terminated
Conditions
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami Springs, Florida, United States, 33166
- Galiz Research
-
-
Missouri
-
O'Fallon, Missouri, United States, 63368
- Psychiatric Care and Research Center
-
Saint Charles, Missouri, United States, 63304
- St. Charles Psychiatric Associates
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19139
- CRI Lifetree
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- - 18 to 65 years of age
- Has a reliable informant (eg, family member, social worker, caseworker, or nurse that spends >4 hours/week with the subject)
- Fixed home/place of residence and can be reached by telephone
- On a stable dose of antipsychotic medications
- Able to swallow capsules
Exclusion Criteria:
- Taking lithium, carbamazepine, lamotrigine, gabapentin, cholinesterase inhibitors, modafinil, or other stimulants such as methylphenidate and other amphetamine products
- Treated with clozapine in past 30 days
- Lifetime history of stimulant, cocaine, or amphetamine abuse or dependence
- History of seizures (other than infantile febrile seizures), any tic disorder, or current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions
- Uncontrolled hypertension
- History of thyroid disorder that has not been stabilized on thyroid medication
- Glaucoma
- Pregnant or nursing
- Subject has received an investigational product or participated in a clinical study within 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
One capsule a day for 26 weeks
|
Experimental: SPD489 Low Dose Range
|
Capsule, dose titration,
Other Names:
|
Experimental: SPD489 High Dose Range
|
Capsule, dose titration,
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Change From Baseline in Simpson Angus Scale (SAS) Total Score at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Change From Baseline in Social Functioning Scale (SFS) at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale
Time Frame: Baseline and week 26
|
Baseline and week 26
|
Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale
Time Frame: Up to 26 weeks
|
Up to 26 weeks
|
Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Up to 26 weeks
|
Up to 26 weeks
|
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 26 Weeks
Time Frame: Baseline and 26 weeks
|
Baseline and 26 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2013
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
January 2, 2013
First Submitted That Met QC Criteria
January 3, 2013
First Posted (Estimate)
January 4, 2013
Study Record Updates
Last Update Posted (Actual)
June 22, 2021
Last Update Submitted That Met QC Criteria
May 29, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Lisdexamfetamine Dimesylate
Other Study ID Numbers
- SPD489-335
- 2012-003919-57 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on SPD489 low dose range (40mg, 80mg, and 100mg)
-
Basilea PharmaceuticaArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...CompletedSolid TumorUnited States, Italy
-
ShireTerminated
-
Yuhan CorporationCompleted
-
Hamilton Health Sciences CorporationUniversity Health Network, Toronto; Dartmouth-Hitchcock Medical Center; Ottawa... and other collaboratorsTerminated
-
Tris Pharma, Inc.Forest LaboratoriesCompletedModerate to Severe Chronic Pain Due to Osteoarthritis of the KneeUnited States
-
Supernus Pharmaceuticals, Inc.CompletedAttention-Deficit/Hyperactivity Disorder (ADHD)United States
-
ShireWithdrawnNegative Symptoms of Schizophrenia
-
Peking University Third HospitalActive, not recruitingOsteoarthritis, KneeChina
-
Indiana UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Type 2 Diabetes MellitusUnited States
-
Boehringer IngelheimCompletedHypertensionAustralia, Austria, Bulgaria, Czech Republic, Ireland, Italy, New Zealand, Russian Federation, Slovakia, Spain, Ukraine, United Kingdom